Berylson Capital Partners’s Ascendis Pharma ASND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $284K | Hold |
1,900
| – | – | 0.69% | 20 |
|
|
2024
Q2 | $259K | Sell |
1,900
-700
| -27% | -$95.5K | 0.66% | 19 |
|
|
2024
Q1 | $393K | Hold |
2,600
| – | – | 0.79% | 23 |
|
|
2023
Q4 | $327K | Hold |
2,600
| – | – | 0.61% | 25 |
|
|
2023
Q3 | $243K | Hold |
2,600
| – | – | 0.62% | 25 |
|
|
2023
Q2 | $232K | Sell |
2,600
-11,000
| -81% | -$982K | 0.66% | 20 |
|
|
2023
Q1 | $1.46M | Buy |
+13,600
| New | +$1.46M | 3.67% | 16 |
|
|
2022
Q4 | – | Sell |
-51,000
| Closed | -$5.27M | – | 20 |
|
|
2022
Q3 | $5.27M | Buy |
+51,000
| New | +$5.27M | 8.7% | 1 |
|
|
2022
Q2 | – | Sell |
-39,400
| Closed | -$4.62M | – | 22 |
|
|
2022
Q1 | $4.62M | Buy |
+39,400
| New | +$4.62M | 5.42% | 4 |
|
|
2021
Q3 | – | Sell |
-70,300
| Closed | -$9.25M | – | 29 |
|
|
2021
Q2 | $9.25M | Sell |
70,300
-22,025
| -24% | -$2.9M | 2.05% | 23 |
|
|
2021
Q1 | $11.9M | Buy |
92,325
+19,625
| +27% | +$2.53M | 2.9% | 13 |
|
|
2020
Q4 | $12.1M | Hold |
72,700
| – | – | 2.07% | 15 |
|
|
2020
Q3 | $11.2M | Buy |
72,700
+14,500
| +25% | +$2.24M | 3.93% | 6 |
|
|
2020
Q2 | $8.61M | Buy |
+58,200
| New | +$8.61M | 5.29% | 7 |
|
|
2019
Q2 | – | Sell |
-8,300
| Closed | -$977K | – | 23 |
|
|
2019
Q1 | $977K | Buy |
+8,300
| New | +$977K | 1.16% | 29 |
|